-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Drug pipeline progress in 2020
- The seeding study was successfully completed.
- Established a strategic cooperation with Bayer and reached a commercial cooperation agreement on Dozaglietin in China
As of December 31, 2020, for the year
- Bank balances and cash amounted to approximately RMB 1.
- In the first half of 2021, it is planned to submit the NDA of dozagliflozin to the China National Medical Products Administration (NMPA)
. - It is planned to carry out research on dozaglietin for diabetic nephropathy in the second half of 2021
. - In the second half of 2021, it is planned to carry out more studies on the combination of dozaglietin, including the combination of GLP-1 inhibitors and insulin in patients with type 2 diabetes, and the study in patients with type 1 diabetes.
Research on combination medication with insulin
.
Expand the clinical pipeline of fixed-dose compound preparations of dozaglietin
.
- In the first half of 2021, it is planned to submit the NDA of dozagliflozin to the China National Medical Products Administration (NMPA)
- Bank balances and cash amounted to approximately RMB 1.
- Established a strategic cooperation with Bayer and reached a commercial cooperation agreement on Dozaglietin in China